Sana Biotechnology's cash burn versus its market cap is worrisome. Despite a notable decrease in its cash burn, the potential need for more funding via new shares could result in costly shareholder dilution.
$Beam Therapeutics(BEAM.US)$$Sana Biotechnology(SANA.US)$ SANA announced an initial payment of 50M using Beam's Cas12b system. It's great for Beam that Cas12b, which Beam doesn't use, is being asked for. The strangest thing is that SANA only needs Cas12b, not Base Editor. It's hard to understand! ?
Sana Biotechnology股票讨论区
• Editing Genes | $CRISPR Therapeutics(CRSP.US)$ , $Intellia Therapeutics(NTLA.US)$ , $Beam Therapeutics(BEAM.US)$ , $Verve Therapeutics(VERV.US)$ , $Editas Medicine(EDIT.US)$
• Creating Therapies | $Prime Medicine(PRME.US)$ , $Sana Biotechnology(SANA.US)$
• Building DNA | $Twist Bioscience(TWST.US)$ , $Ginkgo Bioworks(DNA.US)$ , $Pacific Biosciences of California(PACB.US)$ , $Illumina(ILMN.US)$
• Dis...
• $Repare Therapeutics(RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US)$ +10.2% (In reaction ...
SANA announced an initial payment of 50M using Beam's Cas12b system.
It's great for Beam that Cas12b, which Beam doesn't use, is being asked for. The strangest thing is that SANA only needs Cas12b, not Base Editor. It's hard to understand! ?
暂无评论